In an effort to expand its autoimmune pipeline, Genentech has agreed to collaborate with Parvus Therapeutics to develop and commercialise therapeutics for the treatment of inflammatory bowel disease, autoimmune liver diseases, and celiac disease. The deal will leverage Parvus’ Navacim™ precision medicine platform to generate therapeutics that convert disease-causing effector T-cells to regulatory T cells, which blunt the immune response. This will be Parvus’ second collaboration in the space of just over two years – the first being with Novartis in April 2017.